Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 227

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

HER2/neu-directed therapy for biliary tract cancer

Open access
Javle, Milind, Churi, Chaitanya, Kang, HyunSeon C., Shroff, Rachna, Janku, Filip, Surapaneni, Rakesh, Zuo, Mingxin, Barrera, Christian, Alshamsi, Humaid, Krishnan, Sunil, Mishra, Lopa, Wolff, Robert A., Kaseb, Ahmed O., Thomas, Melanie B., Siegel, Abby B. · 2015 · Journal of Hematology & Oncology

Abstract

BACKGROUND: Biliary cancers are highly aggressive tumors that are often diagnosed an advanced disease stage and have a poor outcome with systemic therapy. Recent efforts towards molecular characterization have identified a subset of biliary patients that have HER2/neu amplification or mutation. HER2/neu amplification is associated with response to HER2/neu-directed therapy in breast and gastric cancers. However, the efficacy of HER2/neu-targeted therapy in biliary cancers is unknown. PATIENTS AND METHODS: We retrospectively reviewed cases of advanced gallbladder cancer and cholangiocarcinoma with HER2/neu genetic aberrations or protein overexpression who received HER2/neu-directed therapy between 2007 and 2014. Clinical data were retrieved from medical records, and imaging studies were independently reviewed. RESULTS: Nine patients with gallbladder cancer and five patients with cholangiocarcinoma had received HER2/neu-directed therapy (trastuzumab, lapatinib, or pertuzumab) during the study period. In the gallbladder cancer group, HER2/neu gene amplification or overexpression was detected in eight cases. These patients experienced disease stability (n = 3), partial response (n = 4), or complete response (n = 1) with HER2/neu-directed therapy. One patient had HER2/neu mutation and experienced a mixed response after lapatinib therapy. The duration of response varied from 8+ to 168 weeks (median 40 weeks), and three patients are still on therapy. One patient developed HER2/neu amplification as a secondary event after FGFR-directed therapy for FGF3-TACC3 gene fusion. The cholangiocarcinoma cases treated in this series had a higher proportion of HER2/neu mutations, and no radiological responses were seen in these patients despite HER2/neu-directed therapy. CONCLUSIONS: HER2/neu blockade is a promising treatment strategy for gallbladder cancer patients with gene amplification and deserves further exploration in a multi-center study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-015-0155-z

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 227

Metadata

Authors
Javle, M., Churi, C., Kang, H. C., Shroff, R., Janku, F., Surapaneni, R., Zuo, M., Barrera, C., Alshamsi, H., Krishnan, S., Mishra, L., Wolff, R. A., Kaseb, A. O., Thomas, M. B., & Siegel, A. B.
Venue
Journal of Hematology & Oncology
Published
2015-05-29
Volume
8
Issue
1
Pages
58-58
ISSN
1756-8722 (ISSN-L)
OpenAlex
W1891752511
Cited by
227
References
4
FWCI
13.94
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER2/neu-directed therapy for biliary tract cancer. https://app.cochat.ai/papers/10.1186/s13045-015-0155-z
The paper
Javle, M., Churi, C., Kang, H. C., Shroff, R., Janku, F., Surapaneni, R., Zuo, M., Barrera, C., Alshamsi, H., Krishnan, S., Mishra, L., Wolff, R. A., Kaseb, A. O., Thomas, M. B., & Siegel, A. B. (2015). HER2/neu-directed therapy for biliary tract cancer. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-015-0155-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.